natgillin/translations-raw huggingface dataset:
VEGF165 for use according to any of claims 1 to 8 wherein said motoneuron disease is amyotrophic lateral sclerosis. 
Čimbenik rasta vaskularnog endotela VEGF165 za uporabu u skladu s bilo kojim patentnim zahtjevom 1 do 8, naznačen time, da je rečena bolest motoneurona amiotrofna lateralna skleroza.
Glutamic acid forms a 1:1 acid addition salt with 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine which is used in the present invention. 
11. Sol prema zahtjevu 7, pri čemu je to adicijska sol glutaminske kiseline 4-[2-(4- metilfenilsulfaniDfenil] piperidina.
and X is I, Br, Cl or mesyl, which is converted to the mitochondrially targeted alkyl-triphenylphosphonium derivative of tamoxifen of the general formula I by heating together with triphenylphosphine. 
VII, gdjen=5do9 iX jel, Br, Clili mesil, koji se zagrijavanjem s trifenil fosfinom pretvara u mitohondrijalni ciljani alkil trifenil fosfonijski derivat tamoksifena opće formule I. 15
Compound 43 was obtained as an oil from compound 42 by method F. 
Spoj 43 se dobiva kao ulje iz spoja 42 pomoću postupka F. i
An ophthalmic device material of Claim 5 wherein the ophthalmic device material comprises a device-forming monomer of formula [IV]: where in formula [IV]: 
Materijal za očne naprave u skladu s patentnim zahtjevom 5, naznačen time što materijal za očne naprave sadrži monomer za oblikovanje naprave formule [TV]: tiv] gdje u formuli [IV]:
An acid addition salt in substantially crystalline form according to claim 1 wherein the crystalline form is selected from forms: 
3. Kiselinska adicijska sol u pretežito kristalnim obliku prema zahtjevu 1, naznačena time da kristalni oblik može biti 10
Alternatively the amide of formula (I) may be prepared by reacting a mixed anhydride derived from the carboxylic acid (11) with the amine NHR4R5 in an aprotic solvent such as tetrahydrofuran. 
Alternativno se amid formule (1) može dobiti reakcijom miješanog anhidrida, dobivenog iz karboksilne kiseline (11) s aminom NHR4Rs, u neprotonskom otapalu, poput tetrahidrofurana.
after the insertion of the capsule into the capsule enclosure space, opening an inlet face of the capsule and injecting a fluid under pressure into the capsule in order to open an outlet face of the capsule. 
- < nakon umetanja čahure u prostor koji obuhvaća čahuru, otvara se ulazna ploha čahure i injektira se fluid pod tlakom u čahuru, da bi se na taj način otvorila izlazna ploha čahure.
S437 P A nucleic acid encoding the polypeptide of one or more of claims 1 to 3, preferably having at least 95% identity to SEQ ID NO: 1. 
S437 P Nukleinska kiselina koja kodira polipeptid prema jednom od patentnih zahtjeva 1 do 3, naznačena time da po mogućnosti ima najmanje 95% identiteta sa SEQ ID NO: 1.
A summary of the crystal data and data refinement parameters for a sample containing a water content of 2.7% is shown in Table 1. 
Sažetak kristalnih podataka i parametri za pročišćavanje podataka za uzorak čiji je sadržaj vode 2,7% prikazan je u Tablici 1.
A composition comprising about 2 mg to about 50 mg of buprenorphine and about 0.5 mg to about 20 mg of Compound-1, wherein Compound-1 has the structure: The composition according to claim 1, comprising about 1.0 to about 20 mg of Compound-1. 
Pripravak koji sadrži 1:1 maseni omjer buprenorfina prema Spoju- 1, pri čemu Spoj- 1 ima strukturu: Pripravak sukladno patentnom zahtjevu 1 sadrži 2 mg do 50 mg buprenorfina. Pripravak sukladno patentnom zahtjevu 1 sadrži 1,0 do 25 mg Spoja- 1.
Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. 
Soli karboksilne skupine mogu se dobiti postupcima poznatima stanju tehnike te uključuju anorganske soli primjerice natrijeve, kalcijeve, amonijeve, željezne ili cinkove soli i si. te soli s organskim bazama kao one koje nastaju na primjer s aminima poput trietanolaminom, argininom ili lizinom, piperidinom, prokainom i sl.
The binding reaction is initiated by addition of radioligand (0.1 nM in 50 ul GnRH binding buffer.) 
Reakcija vezanja započeta je dodavanjem radioliganda (0,1 nM u 50 ul pufer za vezanje GnRH).
The device according to claim 3 wherein the electrodes in the form of the plates are made of titanium covered with metal oxides. The device for producing the sodium hypochlorite or hypochlorous acid according to claim 3, wherein the fixed time period during which the circulating current of low continuous voltage reverses direction, is from 90 minutes to 180 minutes. 
Uređaj (40) za proizvodnju natrijevog hipoklorita ili hipoklorne kiseline prema patentnom zahtjevu 1, naznačen time što su elektrode (28, 29) koje su u obliku ploča i koje mogu biti polarizirane u oba smjera načinjene od titana obloženog metalnim oksidima.
The optical assembly according to claim 1, wherein said primary optical system (2) comprises a plurality of primary reflector elements (21-24), preferably in the form of heliostats and/or mirrors. 
Optički sklop u skladu s patentnim zahtjevom 1, naznačen time, da navedeni primarni optički sustav (2) sadržava veći broj primarnih reflektorskih elemenata (21-24), poželjno u obliku heliostata i / ili zrcala.
Still a further aspect of the present invention is a method for the treatment of a patient suffering from morning stiffness and pain due to an underlying rheumatic disease and/or osteoarthritis, which comprises administering to said patient an effective amount of a glucocorticoid contained in a delayed-release dosage form, wherein said treatment is administered once daily for at least about two weeks. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu u liječenju bolesnika koji pate od jutarnje ukočenosti i boli zbog reumatske podloge bolesti i/ili osteoartritisa, pri čemu se navedeno liječenje provodi davanjem lijeka jednom dnevno kroz najmanje dva tjedna.
The compound of formula (V) is in turn obtained by reacting a compound of formula (VI): 
Spoj formule (V) se pak dobiva reakcijom spoja formule (VI):
filling the feeding bottle (2) via the water fill opening (14) and closing the water fill opening (14) after the feeding bottle (2) has been filled with the correct volume of water; and 
punjenja bočice za bebe (2) kroz otvor za dodavanje vode (14) i zatvaranja otvora za dodavanje vode (14) nakon punjenja bočice za bebe (2) odgovarajućim volumenom vode; i
The wet cake was displacement-washed with 20% aqueous DMAc (300 mL), followed by an additional two batches of 20% aqueous DMAc (400 mL), and finally water (400 mL). 
Mokra masa je isprana sa 20% vodenim DMACc (300 mL), praćeno sa dodatne dvije šarže 20% vodenog DMAc (400 mL), te konačno vodom (400 mL).
Use of an acceleration sensor for determining a displacement of an anchor (1) by integrating, preferably numerically, measured acceleration values twice over time; in a method according to one of claims 1 through 6. 
13. Upotreba senzora ubrzanja za određivanje pomaka sidra (1) integrirajući, po mogućnosti numerički, izmjerene vrijednosti ubrzanja tijekom vremena; u postupku prema jednom od patentnih zahtjeva od I do 6.
correlating the response of the patients treated with the HER dimerization inhibitor to the level of expression of the marker protein encoded by the marker gene or the combination of marker proteins encoded by the marker genes determined in step a) thereby determining the threshold value. 
Postupak prema zahtjevu 1, naznačen time, da korak a) određivanje marker-proteina kodiranog marker-genom ili kombinacijom marker-proteina kodiranih marker-genima, sadrži a1) određivanje razine ekspresije marker-proteina kodiranog marker-genom ili kombinacijom marker-proteina kodiranih marker-genima, a2) utvrđivanje da li je razina ekspresije određena u koraku a1) iznad ili ispod granične vrijednosti.
With reference to FIG. 3 the thickness reduction starts in the mould itself, wherein the slab undergoes a first reduction in its central portion where the crown is provided, goes on in the how caster, with the liquid core thickness reduction and ends with the last rolling stand. 
S obzirom na Sliku 3, smanjenje debljine počinje u samom kalupu, gdje slab prolazi kroz prvo smanjenje u svom središnjem dijelu gdje se nalazi krunica, zatim ide u odljev oblika luka, uz smanjenje debljine tekuće jezgre te završava na zadnjem valjačkom stanu.
The wire fence according to claim 3, wherein the hinge joint (20, 16') of an interior line wire (12i) is formed with end portions of two intersecting transverse wires (14i-1, 14i) coming from respective adjacent line wires. 
Žičana ograda u skladu s patentnim zahtjevom 3, naznačena time što je zglobni spoj (20, 16") unutarnje linijske žice (12;) načinjen s krajnjim dijelovima dvije ukrižene poprečne žice (14;,, 14) koji izlaze iz odgovarajućih susjednih linijskih žica.
R6 hydroxyl, OP2, R7COO or an ether functionality such as an O-methylthiomethyl or other 
hidroksil, OP», R;CO00 1li eterska funkcionalna skupina kao što je O-metiltiometil ili drugi hetero supstituirani eteri
The antibody of any one of items 1 to 5, which is not substantially capable of binding to CLDN4 associated with the surface of a cell that expresses CLDN4 and/or is not substantially capable of binding to CLDN3 associated with the surface of a cell that expresses CLDN3. 
Antitijelo prema patentnom zahtjevu 1, koje nije sposobno da se detektabilno veže za CLDN4 povezan s površinom stanice koja eksprimira CLDNA i/ili nije sposobno da se detektabilno veže za CLDN3 povezan s površinom stanice koja eksprimira CLDN3, pri čemu je vezanje antitijela za CLDN4 i CLDN3 određeno pomoću protočno citometrijske analize kao vezanje antitijela za CLDN4 i CLDN3 eksprimiranih na površini intaktnih stanica.
The pharmaceutical composition according to any one of claims 1-2, wherein the sense strand comprises SEQ ID NO:101 and the antisense strand comprises SEQ ID NO:168; wherein the sense strand further comprises 2'-O-methyl modified ribonucleotides in positions 4, 11, 13, and 17; a C3OH non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5'-terminus; and wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides in positions 1, 4, 8, 13 and 15; a 2'-5'-ribonucleotide in position 6; and a C3Pi-C3OH moiety covalently attached at the 3'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:101, a protusmisleni lanac sadrži SEQ ID NO:168; gdje smisleni lanac dodatno sadrži 2'-O-metilom modificirane ribonukleotide na položajima 4, 11, 13, 1 17; C3OH nenukleotidni ostatak kovalentno vezan na 3'- kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5'-kraju; i gdje protusmisleni lanac dodatno sadrži 2'-O-metilom modificirane ribonukleotide na položajima 1, 4, 8, 13 i 15; 2'-5'-ribonukleotid na položaju 6; i C3Pi-C30H ostatak kovalentno vezan na 3'-kraju.
When the reagent used is a carboxyl anhydride, an exemplary procedure (as shown in Figure 18) is as follows. 
Kada je reagens koji se koristi karboksil anhidrid, slijedi postupak koji je prikazan kao primjer (kao što je prikazano na slici 18).
Method according to claim 9, wherein the negative acknowledgement for the first part (2,3,4) of missing data units comprised in the reduced status message is represented by as many negative acknowledgements as fitted in the reduced status message because of limited resources. 
Postupak prema zahtjevu 4, gdje je negativna potvrda za prvi dio (2,3,4) podatkovnih jedinica koje nedostaju, a koja je sadržana u reduciranoj poruci o statusu, predstavljena s toliko negativnih potvrda koliko stane u reduciranu poruku o statusu zbog ograničenih resursa.
The use according to claim 27, characterized in that said cancer is a cancer selected among prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer, multiple myeloma, ovarian cancer, pancreatic cancer and colon cancer. 
Antitijelo ili njegov funkcionalni fragment i/ili pripravak prema patentnom zahtjevu 20, naznačeno time da je rečeni karcinom odabran od sljedećih: karcinom prostate, osteokarcinom, karcinom pluća, karcinom dojke, karcinom endometrija, multipla mieloma, karcinom jajnika, karcinom pankreasa i karcinom crijeva.
The cell according to Claim 5, which is a eukaryotic cell. 
Stanica prema zahtjevu 9, koja je eukariotska stanica, poželjno stanica sisavca.
The immunogenic composition according to any one of clauses 1 to 26, wherein the M72 related antigen comprises the amino acid sequence of SEQ ID No: 3. 
Imunogeni pripravak u skladu s patentnim zahtjevom 19, naznačen time što antigen povezan s M72 ima aminokiselinski slijed sa SEQ ID No: 3.
The autonomous equipped underwater vehicle (100) according to any of the previous claims, wherein said gravimetric gradiometer (5) comprises two accelerometers having a sensitivity of 1 EPMATHMARKEREP within a range of frequencies lower than 10-1Hz. 
Autonomno opremljeno podvodno vozilo (100) sukladno bilo kojem od prethodnih Zahtjeva, pri čemu se navedeni MA gravimetrijski gradiometar (5) sastoji od dva akcelerometra osjetljivosti 1 "#& unutar opsega frekvencija nižih od 19/Hz.
The use of a compound, pharmaceutically acceptable salt thereof or composition according to any of claims 1-4 in the manufacture of a medicament for the treatment of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction: epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT): voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Uporaba spoja, njegove farmaceutski prihvatljive soli ili smjese prema bilo kojem od zahtjeva 1-4 u proizvodnji lijeka za liječenje bolesti ili stanja izabranih između; emocionalna nestabilnost; pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskinezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropatska bol; bol posredovana simpatikusom; bol povezana s disfunkcijom probavnog sustava; epileptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom.
Aspect 15. The composition of Aspect 13 or 14, further comprising a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Smjesa prema patentnim zahtjevima 3 ili 4, dalje sadrži drugo terapijsko sredstvo korisno u liječenju ili prevenciji bolesti ili stanja izabranih između: emocionalne nestabilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja svijesti; kardiovaskularnih bolesti; glaukoma; tardivnih diskinezija; dijabetičkih neuropatija; retinopatijskih bolesti; bolesti ili poremećaja uzrokovanih apoptozom koje su inducirane homocisteinom; bolesti ili poremećaja uzrokovanih povišenim razinama homocistema; kroničnog bola; intraktabilnog bola; neuropatskog bola; bola posredovanog simpatikusom; bola povezanog s disfunkcijom probavnog sustava; epileptičkih napadaja; tinitusa; seksualnih disfunkcija; intraktabitnog kašlja; dermatitisa; poremećaja ovisnosti; Rettov-og sindroma (RTT); poremećaja glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog rakom.
A process according to claim 10 wherein the palladium catalyst is a ligandless palladium catalyst or a palladium complex catalyst. 
Postupak prema zahtjevu 10, naznačen time da paladijev katalizator jest slobodan paladijev katalizator ili kompleksan paladijev katalizator.
The method of any of claims 1-13, wherein the vaccine comprises diphtheria toxoid and/or tetanus toxoid adsorbed onto aluminium hydroxide, or aluminium phosphate, or a mixture of both, wherein adsorption takes place either before or after mixing with other antigens. 
antigen virusa hepatitisa A, gdje je svaka komponenta izborno apsorbirana na aluminijev hidroksid ili aluminijev fosfat ili na smjesu obojeg; ili gdje je komponenta i), ii) ili iii) izborno neapsorbirana na adjuvans.
the pharmaceutical composition is free of mammalian proteins other than said mature elastase protein; 
(1i) farmaceutski sastav je bez proteina sisara, osim spomenute zrele protein elastaze;
• deposition of obtained dough on the pre-heated special cooking plates in such manner to ensure smooth diffusion having identical diameter. 
odlaganje dobivenog tijesta na prethodno zagrijane specijalne ploče za kuhanje na takav način kako bi se osigurala glatka difuzija.
The odour-absorbing composition according to claim 1, wherein the amount of said B-cyclodextrins is equal to or higher than the total amount of said a-, and Y-cyclodextrins. 
Sastav koji apsorbira neugodne mirise prema patentnom zahtjevu 1, naznačen time, da je količina navedenih B-ciklodekstrina jednaka ukupnoj količini ili je veća od ukupne količine navedenih a- i Y-ciklodekstrina.
The compound according to claim 1, 2 or 3 wherein ring B and the pyrimidine to which it is fused form a ring system selected from wherein 
Spoj prema zahtjevu 1, 2 ili 3 naznačen time da prsten B i pirimidin na koji je kondenziran tvore prstenasti sustav odabran od
at least 1:1, or at least 2:1; respectively, in an aqueous simulated small intestine inorganic buffer ("SIB") containing 36 mM NaCl, 20 mM NaH2PO4, and 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffered to pH 5.5 and at 37 °C. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da umreženi aminski polimer ima odgovarajući molarni omjer vezanja kloridnog iona prema fosfatnom od najmanje 0,5: 1, u vodenom neorganskom puferu koji simulira tanko crijevo ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4, i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) puferiran na pH 5,5 i na 37 °C.
two additional Fab fragments of an antibody which specifically binds to a second antigen, wherein said additional Fab fragments are fused both via a peptide connector either at the C- or N-termini of the heavy chains of a); 
dva dodatna Fab-fragmenta od protutijela koje se specifično veže na drugi antigen, pri čemu su spomenuti dodatni Fab-fragmenti sjedinjeni oba putem peptidne poveznice, bilo na C-završetku ili na N-završetku od jakih lanaca iz točke (a);
The antigen binding protein of the invention may comprise a heavy chain of SEQ ID NO:62 and/or a light chain variable region of SEQ ID NO:64. 
Stanica domaćin u skladu s patentnim zahtjevom 1, naznačena time što prvi vektor kodira laki lanac sa SEQ ID NO: 64, a drugi vektor kodira teški lanac sa SEQ ID NO:62.
L -Y-glutamyl-3-[(phenylmethyl)sulfonyl]- L -alanyl- D -phenylglycine dimethyl ester, 1C, as the hydrochloride salt, was prepared from 500 mg (0.98 mmol) L -Y-glutamyl-S-(phenylmethyl)- L -cysteinyl- D -phenylglycine hydrochloride using the method of Synthetic Example 3, using methanol instead of isopropanol in the esterification, and oxidizing the dimethyl ester in the same way as for the diisopropyl ester, with three dissolution/lyophilization cycles used for purification. 
L-y-glutamil-3-[(fenilmetil)sulfonil]-1-analil-D-fenil glicin dimetil ester, 1C kao hidrokloridna sol, pripravljen je iz 500 mg L-y-glutamil-S-(fenilmetil)-1-cisteinil-D-fenil glicin hidroklorida korištenjem postupka iz Primjera sinteze 3, upotrebom metanola umjesto izopropanpla u esterifikaciji, i oksidacijom dimetil estera na isti način kao i za diizopropil ester, sa tri ciklusa otapanje/lipofilizacija korištena za pročišćavanje.
Silicified microcrystalline cellulose 
Mikrokristalinična celuloza sa silicijem
The crystal according to [2], wherein its powder X-ray diffraction spectrum has a pattern shown in FIG. 1; 
Kristal prema zahtjevu 2, naznačen time što njegov spektar difrakcije rendgenskih zraka na prahu ima uzorak prikazan na Slici 1.
inflating the liner with air; and curing the resin with steam. The method of claim 1, including providing a continuous length of liner and cutting the liner when the liner is pulled into the predetermined distance from the installation access opening. 
Metoda 1z patentnog zahtjeva 1, uključujući opskrbu podloškom neprekinute duljine (11, 74, 86, 101) i rezanje podloška kada je podložak uvučen u predodređenu udaljenost od pristupnog instalacijskog otvora (113).
a human pathogen, and the therapeutic antibody specifically binds an epitope of the human pathogen; 
(a) humani patogen, a terapijsko antitijelo se specifično vezuje za epitop humanog patogena;
A method for enhancing growth rate of cells in cell culture comprising culturing cells in culture media comprising an amount of dodecyldimethylamine oxide (DDAO) or a related analyte sufficient to improve the growth rate of the cells in culture, wherein the analyte is selected from the group consisting of C10 dimethylamine oxide, C12 dimethyl amine oxide, C14 dimethyl amine oxide, C16 dimethylamine oxide, C18 dimethylamine oxide, dimethyl-tetradecyl-amine-oxide and dimethyl-hexadecyl-amine-oxide. 
što je AANOx DDAO ili srodni analit koji se bira iz skupine koju čine dimetil(tetradeciljamin-oksid (CI4NC20), dimetil(heksadeciljamin-oksid (C16NC20), a analite AANOx se bira iz skupine koju čine C10 dimetilamin-oksid, C12 dimetilamin-oksid, C14 dimetilamin-oksid i C16 dimetilamin-oksid.
a first anchoring pipe fixed to a seabed or other geological formation where an underground reservoir to be exploited lies, the first anchoring pipe situated close to a surface of the seabed or the other geological formation; 
prvu sidrenu cijev (30), pričvršćenu na morsko dno ili koju drugu geološku formaciju, gdje leži podzemni spremnik koji će se eksploatirati, gdje se prva sidrena cijev (30) nalazi blizu površine morskog dna ili koja druge geološke formacije u pitanju;
An isolated IL-23p19 antibody, which is an antibody that binds to the p19 subunit of IL-23, comprising: 
PATENTNI ZAHTJEVI Izolirano IL-23p19 antitijelo, koje je antitijelo koje se veže za p19 podjedinicu IL-23, obuhvaćajući:
Formulation ET-NF-G is a preferred formulation. 
Oblik ET-NF-G je poželjni oblik.
The pharmaceutical composition of any one of claims 1 to 6, wherein said AvPAL variant further comprises a water-soluble polymer. 
Farmaceutski sastav 1z bilo kojeg od patentnih zahtjeva 1 do 6, pri čemu navedena AvPAL varijanta nadalje sadrži polimer topljiv u vodi.